Lv63
1780 积分 2023-06-20 加入
Tumour heterogeneity and resistance to cancer therapies
14天前
已完结
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer
20天前
已完结
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
25天前
已完结
A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
25天前
已完结
Management of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline
1个月前
已关闭
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer
1个月前
已完结
P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
1个月前
已关闭
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancer
1个月前
已完结
Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study
1个月前
已关闭
New Option for Patients With Allergy to Chemotherapy Component
1个月前
已关闭
皖公网安备34019202002308
